Next-generation CDK inhibitors in HR+/HER2- breast cancer. Seriak D, Kim JY, Shapiro GI, Giordano A, et al. J Clin Invest 2026;136:e207631.

Read + Share

Amedeo Smart

Independent Medical Education

Seriak D, Kim JY, Shapiro GI, Giordano A, et al. Next-generation CDK inhibitors in HR+/HER2- breast cancer. J Clin Invest 2026;136:e207631.
PMID: 42878072